Literature DB >> 28079542

Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.

Marc A Attiyeh1, Carlos Fernández-Del Castillo2, Mohammad Al Efishat1, Anne A Eaton3, Mithat Gönen3, Ruqayyah Batts1, Ilaria Pergolini2, Neda Rezaee4, Keith D Lillemoe2, Cristina R Ferrone2, Mari Mino-Kenudson5, Matthew J Weiss4, John L Cameron4, Ralph H Hruban6, Michael I D'Angelica1, Ronald P DeMatteo1, T Peter Kingham1, William R Jarnagin1, Christopher L Wolfgang4, Peter J Allen1.   

Abstract

OBJECTIVE: Previous nomogram models for patients undergoing resection of intraductal papillary mucinous neoplasms (IPMNs) have been relatively small single-institutional series. Our objective was to improve upon these studies by developing and independently validating a new model using a large multiinstitutional dataset. SUMMARY BACKGROUND DATA: IPMNs represent the most common radiographically identifiable precursor lesions of pancreatic cancer. They are a heterogenous group of neoplasms in which more accurate markers of high-grade dysplasia or early invasive carcinoma could help avoid unnecessary surgery in 1 case and support potentially curative intervention (resection) in another.
METHODS: Prospectively maintained databases from 3 institutions were queried for patients who had undergone resection of IPMNs between 2005 and 2015. Patients were separated into main duct [main and mixed-type (MD)] and branch duct (BD) types based on preoperative imaging. Logistic regression modeling was used on a training subset to develop 2 independent nomograms (MD and BD) to predict low-risk (low- or intermediate-grade dysplasia) or high-risk (high-grade dysplasia or invasive carcinoma) disease. Model performance was then evaluated using an independent validation set.
RESULTS: We identified 1028 patients who underwent resection for IPMNs [MD: n = 454 (44%), BD: n = 574 (56%)] during the 10-year study period. High-risk disease was present in 487 patients (47%). Patients with high-risk disease comprised 71% and 29% of MD and BD groups, respectively (P <0.0001). MD and BD nomograms were developed on the training set [70% of total (n = 720); MD: n = 318, BD: n = 402] and validated on the test set [30% (n = 308); MD: n = 136, BD: n = 172]. The presence of jaundice was almost exclusively associated with high-risk disease (57 of 58 patients, 98%). Cyst size >3.0 cm, solid component/mural nodule, pain symptoms, and weight loss were significantly associated with high-risk disease. C-indices were 0.82 and 0.81 on training and independent validation sets, respectively; Brier scores were 0.173 and 0.175, respectively.
CONCLUSIONS: For patients with suspected IPMNs, we present an independently validated model for the prediction of high-risk disease.

Entities:  

Keywords:  cancer; dysplasia; intraductal papillary mucinous neoplasm; IPMN; nomogram; pancreas; the pancreatic surgery consortium

Mesh:

Year:  2018        PMID: 28079542      PMCID: PMC5565720          DOI: 10.1097/SLA.0000000000002015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

Review 2.  Nomograms in oncology: more than meets the eye.

Authors:  Vinod P Balachandran; Mithat Gonen; J Joshua Smith; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

Review 3.  Precursors to invasive pancreatic cancer.

Authors:  Anirban Maitra; Noriyoshi Fukushima; Kyoichi Takaori; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2005-03       Impact factor: 3.875

4.  Validity of the management strategy for intraductal papillary mucinous neoplasm advocated by the international consensus guidelines 2012: a retrospective review.

Authors:  Yusuke Watanabe; Kazuyoshi Nishihara; Yusuke Niina; Yuji Abe; Takao Amaike; Shin Kibe; Yusuke Mizuuchi; Daisuke Kakihara; Minoru Ono; Sadafumi Tamiya; Satoshi Toyoshima; Toru Nakano; Shoshu Mitsuyama
Journal:  Surg Today       Date:  2015-12-21       Impact factor: 2.549

5.  Validation of a nomogram for predicting the probability of carcinoma in patients with intraductal papillary mucinous neoplasm in 180 pancreatic resection patients at 3 high-volume centers.

Authors:  Yasuhiro Shimizu; Hiroki Yamaue; Hiroyuki Maguchi; Kenji Yamao; Seiko Hirono; Manabu Osanai; Susumu Hijioka; Yukihide Kanemitsu; Tsuyoshi Sano; Yoshiki Senda; Vikram Bhatia; Akio Yanagisawa
Journal:  Pancreas       Date:  2015-04       Impact factor: 3.327

6.  The management of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Peter J Allen
Journal:  Surg Oncol Clin N Am       Date:  2010-04       Impact factor: 3.495

7.  Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram.

Authors:  Camilo Correa-Gallego; Richard Do; Jennifer Lafemina; Mithat Gonen; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; Murray F Brennan; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

8.  Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kazuyuki Nagai; Ryuichiro Doi; Tatsuo Ito; Atsushi Kida; Masayuki Koizumi; Toshihiko Masui; Yoshiya Kawaguchi; Kohei Ogawa; Shinji Uemoto
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-03-12

Review 9.  Management of intraductal papillary mucinous neoplasms.

Authors:  Stefano Crippa; Carlos Fernández-del Castillo
Journal:  Curr Gastroenterol Rep       Date:  2008-04

10.  Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation.

Authors:  J Lafemina; N Katabi; D Klimstra; C Correa-Gallego; S Gaujoux; T P Kingham; R P Dematteo; Y Fong; M I D'Angelica; W R Jarnagin; R K Do; M F Brennan; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2012-10-31       Impact factor: 5.344

View more
  36 in total

Review 1.  The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?

Authors:  Jenny Lim; Peter J Allen
Journal:  Updates Surg       Date:  2019-06-07

2.  Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

3.  Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.

Authors:  Seiko Hirono; Yasuhiro Shimizu; Takao Ohtsuka; Toshifumi Kin; Kazuo Hara; Atsushi Kanno; Shinsuke Koshita; Keiji Hanada; Masayuki Kitano; Hiroyuki Inoue; Takao Itoi; Toshiharu Ueki; Toshio Shimokawa; Susumu Hijioka; Akio Yanagisawa; Masafumi Nakamura; Kazuichi Okazaki; Hiroki Yamaue
Journal:  J Gastroenterol       Date:  2019-08-28       Impact factor: 7.527

Review 4.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

5.  Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis.

Authors:  Marc A Attiyeh; Jayasree Chakraborty; Lior Gazit; Liana Langdon-Embry; Mithat Gonen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Peter J Allen; Richard K Do; Amber L Simpson
Journal:  HPB (Oxford)       Date:  2018-08-07       Impact factor: 3.647

Review 6.  Comparative Effectiveness of Resection vs Surveillance for Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasms With Worrisome Features.

Authors:  Yinin Hu; Lily E. Johnston; Vanessa M. Shami; Todd W. Bauer; Reid B. Adams; George J. Stukenborg; Victor M. Zaydfudim
Journal:  JAMA Surg       Date:  2018-03-01       Impact factor: 14.766

7.  Development and validation of prognostic nomograms for patients with metastatic prostate cancer.

Authors:  Wei-Dong Jiang; Ping-Cheng Yuan
Journal:  Int Urol Nephrol       Date:  2019-07-09       Impact factor: 2.370

8.  CT radiomics to predict high-risk intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Jayasree Chakraborty; Abhishek Midya; Lior Gazit; Marc Attiyeh; Liana Langdon-Embry; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  Med Phys       Date:  2018-09-27       Impact factor: 4.071

9.  Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms.

Authors:  Kate A Harrington; Travis L Williams; Sharon A Lawrence; Jayasree Chakraborty; Mohammad A Al Efishat; Marc A Attiyeh; Gokce Askan; Yuting Chou; Alessandra Pulvirenti; Caitlin A McIntyre; Mithat Gonen; Olca Basturk; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; William R Jarnagin; Jeffrey A Drebin; Richard K Do; Peter J Allen; Amber L Simpson
Journal:  J Med Imaging (Bellingham)       Date:  2020-06-25

Review 10.  The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Authors:  Eugene J Koay; William Hall; Peter C Park; Beth Erickson; Joseph M Herman
Journal:  Abdom Radiol (NY)       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.